Progress against GI cancer during the American Society of Clinical Oncology's first 50 years

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1521-1530

  Mayer, Robert J ^a   Venook, Alan P ^b   Schilsky, Richard L ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANUS CANCER; ARTICLE; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ESOPHAGUS CANCER; HEPATOBILIARY SYSTEM CANCER; HUMAN; INTERSTINAL CARCINOID TUMOR; INTESTINE TUMOR; MEDICAL SOCIETY; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; STOMACH CANCER; FORECASTING; GASTROINTESTINAL TUMOR; HISTORY; MASS COMMUNICATION; ONCOLOGY; TIME; TREATMENT OUTCOME; UNITED STATES;

DIFFUSION OF INNOVATION; FORECASTING; GASTROINTESTINAL NEOPLASMS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MEDICAL ONCOLOGY; SOCIETIES, MEDICAL; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84903776035     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.4121     Document Type: Article

References (148)

1. [No authors listed]: Statistics on cancer. CA Cancer J Clin 17:34-43, 1967
2. Siegel R, Ma J, Zou Z: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
3. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
4. Moertel CG, Childs DS Jr, Reitemeier RJ, et al: Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2:865-867, 1969
5. Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289, 1991
6. Wynder EL, Mabuchi K: Cancer of the gastrointestinal tract: Etiological and environmental factors. JAMA 226:1546-1548, 1973
7. Cook MB, Chow WH, Devesa SS: Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 101:855-859, 2009
8. Lagergren J, Bergström R, Lindgren A, et al: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825-831, 1999 (Pubitemid 29142625)
9. Spechler SJ: Barrett esophagus and risk for esophageal cancer: A clinical review. JAMA 310:627-636, 2013
10. Turati F, Tramacere I, La Vecchia C, et al: A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 24:609-617, 2013
11. Reid BJ, Li X, Galipeau PC, et al: Barrett's esophagus and oesophageal adenocarcinoma: Time for a new synthesis. Nat Rev Cancer 10:87-101, 2010
12. Moertel CG: Alimentary tract cancer: The esophagus, in Holland JR, Frei E III (eds): Cancer Medicine. Lea & Febiger, Philadelphia, PA, 1973, p1523
13. Biere SS, van Berge Henegouwen MI, Maas KW, et al: Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: A multicenter, open-label, randomized controlled trial. Lancet 379:1887-1892, 2012
14. Sjoquist KM, Burmeister BH, Smithers BM, et al: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated metaanalysis. Lancet Oncol 12:681-692, 2011
15. van Hagen P, Hulshof MC, van Lanschot JJ, et al: Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084, 2012
16. Bedenne L, Michel P, Bouché O, et al: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25:1160-1168, 2007 (Pubitemid 46640561)
17. Stahl M, Stuschke M, Lehmann N, et al: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310-2317, 2005 (Pubitemid 46218723)
18. Lordick F, Ott K, Krause BJ, et al: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 8:797-805, 2007 (Pubitemid 47308659)
19. Wiggins CL, Becker TM, Key CR, et al: Stomach cancer among New Mexico's American Indians, Hispanic whites, and non-Hispanic whites. Cancer Res 49:1595-1599, 1989 (Pubitemid 19088703)
20. Hanley AJ, Choi BC, Holowaty EJ: Cancer mortality among Chinese migrants: A review. Int J Epidemiol 24:255-265, 1995 (Pubitemid 26428803)
21. Chyou PH, Nomurg AM, Hanker JH, et al: A case-cohort study of diet and stomach cancer. Cancer Res 50:7501-7504, 1990
22. Uemura N, Okamoto S, Yamamoto S, et al: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784-789, 2001
23. Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinomas - An attempt at histo-clinical classification. Acta Pathol Microbiol Scand 64:31-49, 1965
24. Kaurah P, MacMillan A, Boyd N, et al: Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297:2360- 2372, 2007
25. Bozzetti F, Marubini E, Bonfanti G, et al: Subtotal versus total gastrectomy for gastric cancer: Five-year survival rates in a multicenter randomized Italian trial-Italian Gastrointestinal Tumor Study Group. Ann Surg 230:170-178, 1999 (Pubitemid 30191882)
26. 2 trial. Lancet Oncol 11:439-449, 2010
27. Power DG, Kelsen DP, Shah MA: Advanced gastric cancer: Slow but steady progress. Cancer Treat Rev 36:384-392, 2010
28. Bang YJ, Van Cutsem E, Feyereislova A, et al: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet 376:687-697, 2010
29. Ohtsu A, Shah MA, Van Cutsem E, et al: Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A randomized double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968-3976, 2011
30. Fuchs CS, Tomasek J, Yong CJ, et al: Ramucirurab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international randomised multicentre, placebo-controlled, phase 3 trial. Lancet 383:31-39, 2014
31. Wilke H, Van Cutsem E, Oh SC, et al: RAINBOW: A global, phase III, randomized, double-blind study of ramucirurab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinumand fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE). J Clin Oncol 32, 2014 (suppl 3; abstr LBA7)
32. 2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet 379:315-321, 2012
33. Sasako M, Sakuramoto S, Katai H, et al: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387-4393, 2011
34. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
35. Smalley SR, Benedetti JK, Haller DG, et al: Updated analysis of SWOG-directed Intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-2333, 2012
36. Fuchs CS, Tepper JE, Niedzwiecki D, et al: Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT: Intergroup trial CALGB 80101. J Clin Oncol 29:45s, 2011 (suppl; abstr 4003)
37. Edis AJ, Kiernan PD, Taylor WF: Attempted curative resections of ductal carcinoma of the pancreas: Review of Mayo Clinic experience, 1951-1975. Mayo Clin Proc 55:531-536, 1980 (Pubitemid 11166443)
38. McCune WS, Shorb PE, Moscovitz H: Endoscopic cannulation of the ampulla of Vater: A preliminary report. Ann Surg 167:752-756, 1968
39. Faigel DO, Ginsberg GG, Bentz JS, et al: Endoscopic ultrasound-guided real-time fine-needle aspiration biopsy of the pancreas in cancer patients with pancreatic lesions. J Clin Oncol 15:1439-1443, 1997 (Pubitemid 27167377)
40. Yeo CJ, Cameron JL, Sohn TA, et al: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, and outcomes. Ann Surg 226:248-260, 1997
41. Feig C, Gopinathan A, Neesse A, et al: The pancreas cancer microenvironment. Clin Cancer Res 18:4266-4276, 2012
42. Jones S, Zhang X, Parsons DW, et al: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-1806, 2008
43. Pleskow DK, Berger HJ, Gyves J, et al: Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 110:704-709, 1989 (Pubitemid 19121224)
44. Hruban RH, Adsay NV, Albores-Saavedra J, et al: Pathology of genetically engineered mouse models of pancreatic exocrine cancer: Consensus report and recommendations. Cancer Res 66:95-106, 2006 (Pubitemid 43166014)
45. Li D, Morris JS, Liu J, et al: Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA 301:2553-2562, 2009
46. Gullo L, Pezzilli R, Morselli-Labate AM, et al: Diabetes and the risk of pancreatic cancer. N Engl J Med 331:81-84, 1994 (Pubitemid 24202222)
47. Fuchs CS, Colditz GA, Stamfer MJ, et al: A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 156:2255-2260, 1996 (Pubitemid 26361920)
48. Shi C, Hruban RH, Klein AP: Familial pancreatic cancer. Arch Pathol Lab Med 133:365-374, 2009
49. Kastrinos F, Mukherjee B, Tayob N, et al: Risk of pancreatic cancer in families with Lynch syndrome. JAMA 302:1790-1795, 2009
50. Couch FJ, Johnson MR, Rabe KG, et al: The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16:342-346, 2007 (Pubitemid 46383356)
51. Jones J, Hruban RH, Kamiyama M, et al: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324:217, 2009
52. Kalser MH, Ellenberg SS: Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899-903, 1985 (Pubitemid 15040883)
53. Burris HA III, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997 (Pubitemid 27251144)
54. Oettle H, Neuhaus P, Hochhaus A, et al: Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial. JAMA 310:1473-1481, 2013
55. Neoptolemos JP, Stocken DD, Friess H, et al: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200-1210, 2004 (Pubitemid 38339364)
56. Klinkenbijl JH, Jeekel J, Sahmoud T: Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230:776-784, 1999 (Pubitemid 30191812)
57. Regine WF, Winter KA, Abrams RA, et al: Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 299:1019-1026, 2008 (Pubitemid 351347058)
58. Hidalgo M: Pancreatic cancer. N Engl J Med 362:1605-1617, 2010
59. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer: N Engl J Med 364:1817-1825, 2011
60. Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al: Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 31:23-29, 2013
61. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
62. Beasley RP, Hwang LY, Lin CC, et al: Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 men in Taiwan. Lancet 2:1129-1133, 1981
63. Chang DT, Schellenberg D, Shen J, et al: Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115:665-672, 2009
64. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340:745-750, 1999 (Pubitemid 29114292)
65. Mazzaferro V, Regalia E, Doci R, et al: Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699, 1996 (Pubitemid 26079803)
66. Yao FY, Ferrell L, Bass NM, et al: Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 33:1394-1403, 2001 (Pubitemid 32496976)
67. US Department of Health and Human Services: Organ and Transplantation Network: Transplant annual data reports 2012. http://optn.transplant.hrsa.gov/ data
68. Llovet JM, Real MI, Montaña X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359:1734-1739, 2002 (Pubitemid 34607087)
69. Cheng A, Kang Y, Chen Z, et al: Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 26:215s, 2008 (suppl; abstr A4509)
70. Llovet JM, Ricci S, Mazzaferro V, et al: Sorabenib in advanced hepatocullular carcinoma. N Engl J Med 359:378-390, 2008
71. Llovet JM, Di Bisceglie AM, Bruiz J: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711, 2008
72. Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273-1281, 2010
73. Brazeau P, Vale W, Burgus R, et al: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179:77-79, 1973
74. Kvols LK: Metastatic carcinoid tumors and the carcinoid syndrome: A selective review of chemotherapy and hormonal therapy. Am J Med 81:49-55, 1986
75. Rubin J, Ajani J, Schirmer W, et al: Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 17:600-606, 1999 (Pubitemid 29075248)
76. Raymond E, Dahan L, Raoul JL: Sunitinib maleate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
77. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
78. Chan DS, Lau R, Aune D, et al: Red and processed meat and colorectal cancer incidence: Meta-analysis of prospective studies. PLoS One 6:e20456, 2011
79. Bardou M, Barkun AN, Martel M: Obesity and colorectal cancer. Gut 62:933-947, 2013
80. Eheman C, Henley SJ, Ballard-Barbash R, et al: Annual report to the nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 118:2338-2366, 2012
81. Rothwell PM, Wilson M, Elwin CE, et al: Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376:1741-1750, 2010
82. Chan AT, Arber N, Burn J, et al: Aspirin in the chemoprevention of colorectal neoplasia: An overview. Cancer Prev Res (Phila) 5:164-178, 2012
83. Chan AT, Ogino S, Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302:649-658, 2009
84. Meyerhardt JA, Giovannucci EL, Holmes MD, et al: Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 24:3527-3534, 2006 (Pubitemid 46630522)
85. Patel SG, Ahnen DJ: Familial colon cancer syndromes: An update of a rapidly evolving field. Curr Gastroenterol Rep 14:428-438, 2012
86. Peipins LA, Sandler RS: Epidemiology of colorectal adenomas. Epidemiol Rev 16:273-297, 1994
87. Shaukat A, Mongin SJ, Geisser MS, et al: Long-term mortality after screening for colorectal cancer. N Engl J Med 369:1106-1114, 2013
88. Atkin WS, Edwards R, Kralj-Hans I, et al: Once-only flexible sigmoidoscopy screening in prevention or colorectal cancer: A multicentre randomised controlled trial. Lancet 375:1624-1633, 2010
89. Schoen RE, Pinsky PF, Weissfeld JL, et al: Colorectal cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 366:2345-2357, 2012
90. Johnson CD, Chen M-H, Toledano AY, et al: Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med 359:1207-1217, 2008
91. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al: Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med 351:2704-2714, 2004 (Pubitemid 39665324)
92. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
93. Markowitz SD, Bertagnolli MM: Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 361:2449-2460, 2009
94. The Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487:330-337, 2012
95. Edge SB, Byrd DR, Compton CC, et al (eds): Cancer Staging Handbook from the AJCC Cancer Staging Manual (ed 7). Springer, New York, NY, 2010
96. Chang GJ, Rodriguez-Bigas MA, Skibber JM, et al: Lymph node evaluation and survival after curative resection of colon cancer: Systemic review. J Natl Cancer Inst 99:433-441, 2007 (Pubitemid 47073566)
97. Johnson PM, Porter GA, Ricciardi R, et al: Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer. J Clin Oncol 24:3570-3575, 2006 (Pubitemid 46630528)
98. Wolmark N, Fisher B, Wieand HS, et al: The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer: Results from NSABP (National Surgical Adjuvant Breast and Bowel Project) clinical trials. Ann Surg 199:375-382, 1984 (Pubitemid 14139870)
99. Popat S, Hubner R, Houlston RS: Systemic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618, 2005 (Pubitemid 46224239)
100. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficiency of fluorouracil-based therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
101. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study of the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-474, 2009
102. Ogino S, Shima K, Meyerhardt JA, et al: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from Intergroup trial CALGB 89803. Clin Cancer Res 18:890-900, 2012
103. Salazar R, Roepman P, Capella G, et al: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 29:17-24, 2011
104. Venook AP, Niedzwiecki D, Lopatin M, et al: Biological determinants of tumor recurrence in stage II colon cancer: Validation study of the 12-gene recurrence score in Cancer and Leukemia Group B (CALGB) 9581. J Clin Oncol 31:1775-1781, 2013
105. Yothers G, O'Connell MJ, Lee M, et al: Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin. J Clin Oncol 31:4512-4519, 2014
106. Di B, Li Y, Wei K, et al: Laparoscopic versus open surgery for colon cancer: A meta-analysis of 5-year follow-up outcomes. Surg Oncol 22:e39-e43, 2013
107. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
108. Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan, fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 25:3456-3461, 2007 (Pubitemid 47310883)
109. Van Cutsem E, Labianca R, Bodoky G, et al: Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 27:3117-3125, 2009
110. Allegra CJ, Yothers G, O'Connell MJ, et al: Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: Results of NSABP protocol C-08. J Clin Oncol 29:11-16, 2011
111. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer. A randomized trial. JAMA 307:1383-1393, 2012
112. Kapiteijn E, Marijnen CA, Nagtegaal ID, et al: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638-646, 2001
113. Rödel C, Liersch T, Becker H, et al: Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO/ARO/A10-04 randomised phase 3 trial. Lancet Oncol 13:679-687, 2012
114. Sauer R, Liersch T, Merkel S, et al: Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AR94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 30:1926-1933, 2012
115. Schrag D, Cramer LD, Bach PB, et al: Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 284:3028-3035, 2000 (Pubitemid 32014740)
116. Locker GY, Hamilton S, Harris J, et al: ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24:5313-5327, 2006 (Pubitemid 46631379)
117. Wong SL, Mangu PB, Choti MA, et al: American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493-508, 2010
118. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
119. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomised trial. Lancet 355:1041-1047, 2000 (Pubitemid 30162806)
120. DeGramont A, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2983-2947, 2000
121. Tournigand C, André T, Achille E, et al: FOLFIRI followed by FOLFOX 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 22:229-237, 2004 (Pubitemid 41095086)
122. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001 (Pubitemid 33049527)
123. Twelves C, Wong A, Nowacki MP, et al: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352:2696-2704, 2005 (Pubitemid 41007824)
124. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
125. Hurwitz HI, Tebbutt NC, Kabbinavar F, et al: Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials. Oncologist 18:1004-1012, 2013
126. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004 (Pubitemid 38944402)
127. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
128. Dahabreh IJ, Terasawa T, Castaldi PJ, et al: Systematic review: Anti- epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 154:37-49, 2011
129. Douillard J-Y, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023-1034, 2013
130. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti- epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
131. Hecht JR, Mitchell E, Chidiac T, et al: A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone in metastatic colorectal cancer. J Clin Oncol 27:627-680, 2009
132. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360:563-572, 2009
133. Heinemann V, von Weikersthal LF, Decker T, et al: Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol 31:206s, 2013 (suppl 15; abstr LBA3506)
134. Van Cutsem E, Tabernero J, Lakomy R, et al: Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 30:3499-3506, 2012
135. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
136. Holly EA, Whittemore AS, Aston DA, et al: Anal cancer incidence: Genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 81:1726-1731, 1989 (Pubitemid 19275911)
137. Beahrs OH, Wilson SM: Carcinoma of the anus. Ann Surg 184:422-428, 1976
138. Frisch M, Glimelius B, van den Brule AJ, et al: Sexually transmitted infection as a cause of anal cancer. N Engl J Med 337:1350-1358, 1997 (Pubitemid 27467769)
139. Daling JR, Weiss NS, Klopfenstein LL, et al: Correlates of homosexual behavior and the incidence of anal cancer. JAMA 247:1988-1990, 1982 (Pubitemid 12133712)
140. Melbye M, Coté TR, Kessler L, et al: High incidence of anal cancer among AIDS patients: The AIDS/Cancer Working Group. Lancet 343:636-639, 1994 (Pubitemid 24087808)
141. Palefsky JM, Giuliano AR, Goldstone S, et al: HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365:1576-1585, 2011
142. Nigro ND, Vaitkevicius VK, Considine B Jr: Combined therapy for cancer of the anal canal: A preliminary report. Dis Colon Rectum 17:354-356, 1974
143. Leichman L, Nigro N, Vaitkevicius VK, et al: Cancer of the anal canal: Model for preoperative adjuvant combined modality therapy. Am J Med 78:211-215, 1985 (Pubitemid 15162919)
144. Bartelink H, Roelofsen F, Eschwege F, et al: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organisation for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15:2040-2049, 1997 (Pubitemid 27209535)
145. UKCCCR Anal Cancer Trial Working Party: Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. Lancet 348:1049-1054, 1996
146. Flam M, John M, Pajak TF, et al: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study. J Clin Oncol 14:2527-2539, 1996 (Pubitemid 26300120)
147. Gunderson LL, Winter KA, Ajani JA, et al: Long-term update of US GI Intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/ mitomycin versus fluorouracil/cisplatin. J Clin Oncol 30:4344-4351, 2012
148. Grubbs SS, Polite BN, Carney J Jr, et al: Eliminating racial disparities in colorectal cancer in the real world: It took a village. J Clin Oncol 31:1928-1930, 2013